Journal of Viral Hepatitis

Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials
pp. 551-570(20)
Authors: Chou, R.; Carson, S.; Chan, B. K. S.

Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase
pp. 571-577(7)
Authors: Ward, C. L.; Dev, A.; Rigby, S.; Symonds, W. T.; Patel, K.; Zekry, A.; Pawlotsky, J.-M.; McHutchison, J. G.

Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response
pp. 578-590(13)
Authors: Cuevas, J. M.; Torres-Puente, M.; Jiménez-Hernández, N.; Bracho, M. A.; García-Robles, I.; Carnicer, F.; Olmo, J. D.; Ortega, E.; Moya, A.; González-Candelas, F.

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy
pp. 591-599(9)
Authors: Derbala, M. F.; El Dweik, N. Z.; Al Kaabi, S. R.; Al-Marri, A. D.; Pasic, F.; Bener, A. B.; Shebl, F. M.; Amer, A. M.; Butt, M. T.; Yakoob, R.; John, A.; Al Mohanadi, M.; Al Khinji, M. A.

Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials
pp. 600-606(7)
Authors: Fabrizi, F.; Ganeshan, S. V.; Lunghi, G.; Messa, P.; Martin, P.

Bone marrow-derived mesenchymal stem cells are capable of mediating hepatitis B virus infection in injured tissues
pp. 607-614(8)
Authors: Rong, Q.; Zhang, L.; Su, E.; Li, J.; Liu, Z.; Huang, Z.; Ma, W.; Cao, K.; Huang, J.

High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels
pp. 615-621(7)
Authors: Park, J. Y.; Park, Y. N.; Kim, D. Y.; Paik, Y. H.; Lee, K. S.; Moon, B. S.; Han, K.-H.; Chon, C. Y.; Ahn, S. H.

Hepatitis RNA viruses and hepatocellular carcinoma
pp. 622-622(1)
Author: Garen, A.